Nord/LB Analysts Give Bayer (BAYN) a €102.00 Price Target

Nord/LB set a €102.00 ($121.43) target price on Bayer (FRA:BAYN) in a research report released on Friday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other analysts have also recently weighed in on BAYN. Deutsche Bank set a €124.00 ($147.62) price objective on Bayer and gave the stock a buy rating in a research report on Friday, August 11th. set a €105.00 ($125.00) price objective on Bayer and gave the stock a neutral rating in a research report on Wednesday, August 23rd. Jefferies Group set a €137.00 ($163.10) price objective on Bayer and gave the stock a buy rating in a research report on Wednesday, August 23rd. Warburg Research set a €121.00 ($144.05) price objective on Bayer and gave the stock a buy rating in a research report on Wednesday, August 23rd. Finally, Independent Research set a €120.00 ($142.86) price objective on Bayer and gave the stock a neutral rating in a research report on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of €122.19 ($145.46).

Shares of Bayer (FRA BAYN) opened at €105.15 ($125.18) on Friday. Bayer has a 52-week low of €93.07 ($110.80) and a 52-week high of €123.82 ($147.40).

COPYRIGHT VIOLATION NOTICE: “Nord/LB Analysts Give Bayer (BAYN) a €102.00 Price Target” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/12/nordlb-analysts-give-bayer-bayn-a-102-00-price-target.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply